Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Bevacizumab plus Y-90 SIRT for Unresectable HCC
NCT06397222Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- May 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started May 2024; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06397222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397222.